Strategic Revenue SIGA reported quarterly product-related revenue of 38 million driven by intravenous TPOXX deliveries to the U.S. Strategic National Stockpile and international oral TPOXX sales, indicating strong demand channels that can be expanded with new formulations or dosing options.

Expansion Potential Ongoing collaborations and licensing activities, including exclusive licenses for novel poxvirus monoclonal antibodies and a large development contract with DOD for PEP indications, present avenues to upsell companion diagnostics, delivery systems, or bundled protections.

Clinical Leadership Recent leadership appointment of General John M. Keane as General signals a focus on credibility and regulatory strategy, which can facilitate discussions around government-funded procurement, multi-year supply agreements, and expanded stockpile contracts.

Strategic Partnerships Active partnerships with academic and research institutions (Vanderbilt licensing) and industry collaborations (Calidi Biotherapeutics) indicate openness to co-development and platform integrations that could be leveraged to cross-sell additional antiviral or virotherapy solutions.

Global MarketReadiness Diversified tech stack and international sales to multiple markets, combined with active investments in PEP indications and orthopoxvirus therapies, position SIGA to pursue expanded international distribution, licensing deals, or turnkey supply agreements for new products.